Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax. Late last week, the U.S. Court of ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Merck & Co., Inc. (MRK) is a leading global healthcare company specializing in the research, development, and distribution of prescription medicines, vaccines, and animal health products. Its ...

Merck's shares have declined, making its dividend yield climb and valuation compress, presenting an attractive investment opportunity at current prices. Keytruda, the company's largest drug, continues ...